

# Johannes Bloehdorn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7867350/publications.pdf>

Version: 2024-02-01

64  
papers

2,354  
citations

361045

20  
h-index

214527

47  
g-index

67  
all docs

67  
docs citations

67  
times ranked

3927  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy. <i>Haematologica</i> , 2022, 107, 604-614.	1.7	11
2	Salvage Therapy for Alveolar Echinococcosis—A Case Series. <i>Pathogens</i> , 2022, 11, 333.	1.2	4
3	Obinutuzumab (GA-101), ibrutinib, and venetoclax (G1V) frontline treatment for high-risk chronic lymphocytic leukemia. <i>Blood</i> , 2022, 139, 1318-1329.	0.6	30
4	The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1794-1805.	3.3	1
5	U-RT1 — A new model for Richter transformation. <i>Neoplasia</i> , 2021, 23, 140-148.	2.3	5
6	Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2021, , .	1.7	2
7	MARCKS affects cell motility and response to BTK inhibitors in CLL. <i>Blood</i> , 2021, 138, 544-556.	0.6	14
8	Discovery of Candidate DNA Methylation Cancer Driver Genes. <i>Cancer Discovery</i> , 2021, 11, 2266-2281.	7.7	42
9	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 5395.	5.8	15
10	Interleukin-10 receptor signaling promotes the maintenance of a PD-1 <sup>int</sup> TCF-1 <sup>+</sup> CD8 <sup>+</sup> T <sub>H</sub> cell population that sustains anti-tumor immunity. <i>Immunity</i> , 2021, 54, 2825-2841.e10.	6.6	57
11	Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. <i>Leukemia</i> , 2020, 34, 115-127.	3.3	23
12	Distribution of alveolar echinococcosis according to environmental and geographical factors in Germany, 1992-2018. <i>Acta Tropica</i> , 2020, 212, 105654.	0.9	8
13	DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy. <i>Scientific Data</i> , 2020, 7, 133.	2.4	6
14	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. <i>Blood</i> , 2020, 135, 2402-2412.	0.6	83
15	Follow-up in hepatic alveolar echinococcosis under benzimidazole therapy using computed tomography. <i>Chinese Medical Journal</i> , 2020, 133, 1507-1509.	0.9	2
16	Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). <i>Haematologica</i> , 2020, 105, 2598-2607.	1.7	44
17	Stromal cell protein kinase C- $\beta$ inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	18
18	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020, 136, 47-48.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Robust Discovery of Candidate DNA Methylation Cancer Drivers. <i>Blood</i> , 2020, 136, 33-34.	0.6	0
20	Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Unstable Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 12-13.	0.6	0
21	CLINICAL PRESENTATION AND MOLECULAR CHARACTERISTICS OF CUTANEOUS DLBCL. <i>Hematological Oncology</i> , 2019, 37, 362-362.	0.8	0
22	Simple liver cysts and cystoid lesions in hepatic alveolar echinococcosis: a retrospective cohort study with Hounsfield analysis. <i>Parasite</i> , 2019, 26, 54.	0.8	14
23	Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. <i>Lancet Oncology</i> , 2019, 20, 1576-1586.	5.1	26
24	Worldwide literature on epidemiology of human alveolar echinococcosis: a systematic review of research published in the twenty-first century. <i>Infection</i> , 2019, 47, 703-727.	2.3	80
25	Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, e434-e437.	1.7	144
26	IGF1R as druggable target mediating PI3K- $\hat{r}$ inhibitor resistance in a murine model of chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 534-547.	0.6	51
27	Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 2183-2194.	3.3	19
28	Community-driven development of a modified progression-free survival ratio for precision oncology. <i>ESMO Open</i> , 2019, 4, e000583.	2.0	22
29	S105 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY. <i>HemaSphere</i> , 2019, 3, 4.	1.2	4
30	The involvement of microRNA in the pathogenesis of Richter syndrome. <i>Haematologica</i> , 2019, 104, 1004-1015.	1.7	20
31	FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. <i>Blood</i> , 2019, 133, 830-839.	0.6	56
32	Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvented By Inhibiting the BH4 Domain of BCL-2. <i>Blood</i> , 2019, 134, 1507-1507.	0.6	1
33	Telomere Shortening By Terc Knockout in the E $\hat{\mu}$ -TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival. <i>Blood</i> , 2019, 134, 1732-1732.	0.6	0
34	Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. <i>Leukemia and Lymphoma</i> , 2018, 59, 1614-1623.	0.6	12
35	Lamin B1 regulates somatic mutations and progression of B-cell malignancies. <i>Leukemia</i> , 2018, 32, 364-375.	3.3	25
36	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	0.8	257

#	ARTICLE	IF	CITATIONS
37	NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23. Blood, 2018, 132, 946-946.	0.6	1
38	Primary Extranodal Diffuse Large B-Cell Lymphomas Are Enriched for Mutations in MYD88 and CD79B.. Blood, 2018, 132, 1701-1701.	0.6	3
39	Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL. Blood, 2018, 132, 583-583.	0.6	0
40	Ibrutinib Can Induce Complete Remissions and Sustained Responses in Refractory Cutaneous or Leg-Type Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 4237-4237.	0.6	0
41	MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy. Blood, 2018, 132, 1866-1866.	0.6	0
42	Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option. Blood, 2018, 132, 1580-1580.	0.6	0
43	High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia, 2017, 31, 2623-2629.	3.3	72
44	Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. Leukemia, 2017, 31, 734-738.	3.3	18
45	High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia, 2017, 31, 846-852.	3.3	134
46	Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia. Leukemia, 2017, 31, 1177-1186.	3.3	8
47	Postibrutinib outcomes in patients with mantle cell lymphoma. Blood, 2016, 127, 1559-1563.	0.6	228
48	Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. Leukemia, 2016, 30, 1428-1430.	3.3	19
49	The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia, 2015, 29, 2003-2014.	3.3	17
50	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood, 2014, 124, 420-425.	0.6	14
51	Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in "Ultra High-risk" CLL: Final Results from the CLL20 Phase II Study. Blood, 2014, 124, 1991-1991.	0.6	11
52	MicroRNAs in Hematologic Malignancies. , 2014, , 67-95.		0
53	High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?. Blood, 2014, 124, 1964-1964.	0.6	0
54	High Resolution Genomic Profiling of Primary "Ultra High Risk" and Refractory Chronic Lymphocytic Leukemia: Results from the CLL20 Trial. Blood, 2014, 124, 3288-3288.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Genomic Mechanisms of 17p / TP53 Loss in Primary "Ultra High-risk" and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. <i>Blood</i> , 2014, 124, 2184-2184.	0.6	1
56	Cellular origin and pathophysiology of chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2012, 209, 2183-2198.	4.2	227
57	High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012, 120, 4783-4794.	0.6	179
58	Impact of serum storage conditions on microRNA stability. <i>Leukemia</i> , 2012, 26, 2414-2416.	3.3	133
59	Expression of Cereblon (CRBN) Is Associated with Disease Stage, Genetic Subgroups and Specific Micro-RNAs in Multiple Myeloma. <i>Blood</i> , 2012, 120, 1820-1820.	0.6	3
60	Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.. <i>Blood</i> , 2012, 120, 2874-2874.	0.6	0
61	P53 and microRNAs in chronic lymphocytic leukemia. <i>Journal of Nucleic Acids Investigation</i> , 2011, 2, 8.	0.5	1
62	MicroRNAs in Leukemia. , 2011, , 269-285.		0
63	Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, 969-975.	0.8	177
64	Clonal Evolution in Chronic Lymphocytic Leukemia is Scant in Relapsed But Accelerated in Refractory Cases. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0